

<u>MA (EU) number</u>	<u>(Invented) name</u>	<u>Strength</u>	<u>Pharmaceutical Form</u>	<u>Route of Administration</u>	<u>Immediate Packaging</u>	<u>Content (concentration)</u>	<u>Pack size</u>
EU/1/21/1618/001	Nuvaxovid	--1	Dispersion for injection	Intramuscular use	Vial (glass)	5 mL (10 doses)	10 multidose vials (100 doses)
EU/1/21/1618/002	Nuvaxovid	--1	Dispersion for injection	Intramuscular use	Vial (glass)	2.5 mL (5 doses)	10 multidose vials (50 doses)
EU/1/21/1618/003	Nuvaxovid	--1	Dispersion for injection	Intramuscular use	Vial (glass)	5 mL (10 doses)	2 multidose vials (20 doses)
EU/1/21/1618/004	Nuvaxovid	--1	Dispersion for injection	Intramuscular use	Vial (glass)	2.5 mL (5 doses)	2 multidose vials (10 doses)
EU/1/21/1618/006	Nuvaxovid XBB.1.5	--2	Dispersion for injection	Intramuscular use	Vial (glass)	2.5 mL (5 doses)	10 multidose vials (50 doses)
EU/1/21/1618/008	Nuvaxovid XBB.1.5	--2	Dispersion for injection	Intramuscular use	Vial (glass)	2.5 mL (5 doses)	2 multidose vials (10 doses)

--1

One dose (0.5 mL) contains 5 micrograms of the of SARS-CoV-2 spike protein* and is adjuvanted with Matrix-M.

Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 micrograms) and Fraction-C (7.5 micrograms) of *Quillaja saponaria* Molina extract.

* produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the *Spodoptera frugiperda* species.

--2

One dose (0.5 mL) contains 5 micrograms of the of SARS-CoV-2 (Omicron XBB.1.5) spike protein* and is adjuvanted with Matrix-M.

Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 micrograms) and Fraction-C (7.5 micrograms) of *Quillaja saponaria* Molina extract.

* produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the *Spodoptera frugiperda* species.